The effects of pharmacokinetics of antimicrobials on the evolution of bacterial resistance with particular reference to azithromycin;Auswirkungen der pharmakokinetik von antimikrobiellen substanzen auf die entstehung von bakterieller resistenz mit besonderer berucksichtigung von azithromycin

Wiener Medizinische Wochenschrift

Volumn 150, Issue 3, 2000, Pages 37-41

  Wenisch, Ch ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Azithromycin; Bacterial resistance; Intracellular concentrations; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CELL LEVEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; HUMANS; LACTAMS; QUINOLONES; TIME FACTORS;

EID: 0034106183     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. (1) Adu A, Armour CL: Drug utilisation review (DUR) of the third generation cephalosporins, focus on ceftriaxone, ceftazidime and cefotaxime. Drugs 1995; 50:423-439.
2. (2) ASCP Susceptibility Testing Group: United states geographic bacteria susceptibility patterns. Am J Clin Pathol 1998; 109: 144-52.
3. (3) Baldwin DR, Wise R, Andrews JM, et al Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3: 886-90.
4. (4) Barg N: New resistance mechanisms of common pathogens. Contemp Intern Med 1995; 7:61-69.
5. (5) Barman Balfour JA, Lamb HM: Outpatient parenteral antibacterial therapy of serious infections: The role of ceftriaxone. Dis Manage Health Outcomes 1998; 4:225-236.
6. (6) Barry AL, Fuchs PC, Brown SD: Macrolide resistance among streptococcus pneumoniae and streptococcus pyogenes isolates from out-patients in the USA. J Antimicrob Chemother 1997; 40: 139-140.
7. (7) Benko AS, Cappelletty DM. Kruse JA: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agent Chemother 1996; 40:691-695.
8. (8) Bjorkman J, Huges D, Andersson DI: Virulence of antibiotic-resistant salmonella typhimurium. Proc Natl Acad Sci USA 1998; 95: 3949-53.
9. (9) Blaser J, Stone BB, Groner MC, et al: Comparative study with enoxacin and netilmicin in an pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agent Chemother 1987; 31:1054-60.
10. (10) Bodey GP, Ketchel SJ, Rodriguez V: A randomised study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67:608-16.
11. (11) Bonhoeffer S, Lipsitch M, Levin BR: Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997; 94:12106-12111.
12. (12) Butler JC, Hofmann J, Cetron MS, et al: The continued emergence of drug-resistant streptococcus pneumoniae in the United States: an update from the centers for disease control and prevention's pneumococcal sentinel surveillance system. J Infect Dis 1996; 174:986-93.
13. (13) Butts JD: Intracellular concentrations of antibacterial agents and related clinical implications. Clin Pharmacokinet 1994; 27: 63-84.
14. (14) Castillo del F, Baquero-Artigao F, Garcia-Perea A: Influence of recent antibiotic therapy on antimicrobial resistance of streptococcus pneumoniae in children with acute otitis media in Spain. Pediatr Infect Dis J 1998; 17:94-7.
15. (15) Chiew YF, Yeo SF, Hall MC, et al: Can suspectibility to an antimicrobial be restored by halting its use? The case of streptomycin versus enterobacteriaceae. J Antimicrob Chemother 1998; 41: 247-51.
16. (16) Chopra I, Hodgson J, Metcalf B, et al: New approaches to the control of infections caused by antibiotic-resistant bacteria. JAMA 1996;275:401-403.
17. (17) Courvalin P: The garrod lecture evasion of antibiotic action by bacteria. J Antimicrob Chemother 1996; 37:855-869.
18. (18) Craig WA: Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25:213-7.
19. (19) Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
20. (20) Crokaert F: Long-term persistence of azithromycin: Risk or benefit? Infect Med 1998; 15(Suppl A): 10-14.
21. (21) Dagan R, Abramson D, Leibovitz E, et al: Impaired becteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis 1996; 15:980-985.
22. (22) Doern GV, Pfaller MA, Kugler K, et al: Prevalence of antimicrobial resistance among respiratory tract isolates of streptococcus pneumoniae in North America: 1997 results from the sentry antimicrobial surveillance program. Clinical Infectious Diseases 1998; 27: 764-70.
23. (23) Doern GV: Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99(Suppl 6B): 3S-7S.
24. (24) Doern GV, Brueggemann AB, Pierce G et al: Prevalence of antimicrobial resistance among 723outpatient clinical isolates of moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrobial Agent Chemother 1996; 40(12):2884-2886.
25. (25) Drusano GL, Goldstein FW: Relevance of the alexander project: pharmacodynamic considerations. J Antimicrob Chemother 1996: 38(Suppl A): 141-154.
26. (26) Drusano GL: Role of pharmacokinetics in the outcome of infections. Antimicrob Agent Chemother 1988; 32:289-297.
27. (27) Drusano GL: Infection in the intensive care unit: β-lactamase-mediated resistance among enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis 1998; 27(Suppl 1):S111-116.
28. (28) Fass RJ: Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare tn vitro activities and describe cross-resistance. Antimicrob Agent Chemother 1993; 37:2080-2086.
29. (29) Flemingham D: Antibiotic resistance: Do we need new therapeutic approaches? Chest 1995; 108:70S-78S.
30. (30) Forrest A, Nix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicriob Agent Chemother 1993; 37:1073-1081.
31. (31) Foulds G, Chan KH, Johnson JT, et al: Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991; 10:853-856.
32. (32) Fry DE: The Importance of antibiotic phramacokinetics in critial illness. Am J Surg 1996; 172 (Suppl 6A): 20S-25S.
33. (33) Gehanno P, Lenoir G, Berche P: In vivo correlates for streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agent Chemother 1995; 39:271-272.
34. (34) Gerber AU, Craig WA, Brugger HP, et al: Impact of dosing intervals on acitivity of gentamicin and ticarcillin against pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983; 147: 910-917.
35. (35) Gerber AU: Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections. Scand J Infect Dis 1990; 74(Suppl): 147-154.
36. (36) Gladue RP, Bright GM, Isaacson RE, et al: In vitro an in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agent Chemother 1989; 33:277-282.
37. (37) Gladue RP, Snider ME: Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agent Chemother 1990; 34:1056-1060.
38. (38) Goldsmith CE, Moore JE, Murphy PG: Pneumococcal resistance in the UK. J Antimicrob Chemother 1997; 40(Suppl A): 11-18.
39. (39) Goldstein FW, Acar JF, Alexander Collaborative Group: Antimicrobial resistance among lower respiratory tract isolates of streptococcus pneumoniae: results 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38(Suppl A):71-84.
40. (40) Grimm H, Bauernfeind A: Das Alexander-Projekt-eine internationale Studie über Antibiotika-Sensibilität bakerieller Erreger bei ambulant erworbenen Atemwegsinfektionen. Z antimikrob antineoplast Chemother 1997; 15:93-98.
41. (41) Guggenbichler JP, Kastner U: The influence of antibiotics on the normal flora. Infect Med 1998; 15(Suppl A): 15-22.
42. (42) Hall A, Knowles JR: Directed selective pressure on a β-lactamase to analyse molecular changes involved in development of enzyme function. Nature 1976; 264:803-804.
43. (43) Hawkey PM: Action against antibiotic resistance: no time to lose. The Lancet 1998; 351:1298-1299.
44. (44) Hoberman A, Paradise JL, Block S, et al: Efficacy of amoxicillin/clavulanate for acute otitis media: relation to streptococcus pneumoniae susceptibility. Pediatr Infect Dis J 1996; 15:955-962.
45. (45) Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341-345.
46. th report. Session 1997-98. The Stationery Office 1998:1-108.
47. (47) Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ: The importance of pharacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28:143-160.
48. (48) Jacobs MR: Respiratory tract infection: epidemiology and surveillance. J Chemother 1997; 9(Suppl 3): 10-17.
49. (49) James KL, Palmer SM, Levine DP, et al: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agent Chemother 1996; 40:696-700.
50. (50) Jones RN: Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. Diagn Microbiol Infect Dis 1997; 27:21-28.
51. (51) Jones RN: The emergent needs for basic research, education, and surveillance of antimicrobial resistance: The recommendations and implementation problems facing the report from ASM task force on antibiotics. Diagn Microbiol Infect Dis 1996; 25:153-161.
52. (52) Kastner U, Guggenbichler JP: Beeinflussung der körpereigenen Flora durch verschiedene Antibiotika. Antibiotika Monitor 1998; 5: 80-83.
53. (53) Kastner U, Guggenbichler JP: Influence of macrolide antibiotics on the oral flora. Abstract ICMAS 97.
54. (54) Keil S, Wiedemann B: Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agent Chemother 1997; 41: 1215-1219.
55. (55) Kislak JW, Razavi LMB, Daly AK: Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965; 205:261-268.
56. (56) Klastersky J. Daneau D, Swings G, et al: Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis 1974; 129:187-193.
57. (57) Kresken M, Hafner D: Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa. Chemother J 1996; 4:225-230.
58. (58) Kuschner RA, Trofa AF, Thomas RJ, et al: Use of azithromycin for the treatment of campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21:536-541.
59. (59) Leggett JE, Ebert S, Fantin B, et al: Comparative dose-effect relations at several dosing intervals for beta-lactams, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991; 74(Suppl): 179-184.
60. (60) Leggett JE, Fantin B, Ebert S, et al: Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-292.
61. (61) M'Zali FHM, Heritage J, Gascoyne-Binzi DM, et al: Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated ampe-type b-lactamase exposed during an outbreak of shv-5 extended spectrum b-lactamase in an leeds hospital. J Antimicrob Chemother 1997; 40:823-831.
62. (62) Marchisio P, Principi N, Sala E, et al: Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. Antimicrob Agent Chemother 1996; 40:2732-2736.
63. (63) Martin C, Viviand X, Alaya M, et al: Pentration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans. Antimicrob Agent Chemother 1996; 40:812-815.
64. (64) Moore RD, Lietman PS, Smith CR: Clinical response to amino-glycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99.
65. (65) Murphy GS, Echeverria P, Jackson LR, Arness MK, LeBron C, Pitarangs C: Ciprofloxacin-and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis 1996; 22:868-869.
66. (66) Nightingale CH: Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16:438-443.
67. (67) Olsen KM, San Pedro G, Gann LP et al: Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agent Chemother 1996; 40:2582-2585.
68. (68) Paladino JA, Sperry HE, Backes JM, et al: Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91:462-470.
69. (69) Pallares R, Linares J, Vadillo M, et al: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
70. (70) Patel KB, Xuan D, Tessier PR, et al: Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agent Chemother 1996; 40:2375-2379.
71. (71) Piddock LVJ, Walters RN, Jin Y-F, et al: Prevalence and mechanism of resistance to third-generation cephalosporins in clinically relevant isolates of enterobacteriaceae from 43 hospitals in the UK. J Antimicrob Chemother 1997; 39:177-187.
72. (72) Piddock LVJ: Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man und compromise antimicrobial chemotherapy? J Antimicrob Chemother 1996; 38:1-3.
73. (73) Piscitelli SC, Danzinger LH, Rodvold KA: Clarithromycin and azithromycin: new macrolide antibiotics. Clinical Pharamcy 1992; 11:137-152.
74. (74) Platt R, Erlich SL, Afarian J, et al: Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agent Chemother 1981; 20: 351-355.
75. th interscience conference on antimicrobial agents and chemotherapy (New Orleans). Washington DC: American Society for Microbiology. 1996.
76. (76) Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin:enhanced tissue acitivity and minimal drug interactions. Ann Pharmacother 1998; 32:785-793.
77. (77) Report of the joint committee on the use of antibiotics in animal husbandry and veterinary medicine. London, HM Stationary Office, 1969.
78. (78) Retsema JA, Brennan LA, Girard AE: Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10:834-842.
79. (79) Retsema JA, Girard AE, Brennan LA, et al: Lack of emergence of significant resistance in vitro and vivo to the new azalide antibiotic azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10:843-846.
80. (80) Roosendaal R, Bakker-Woudenberg IAJM, van den Berge-van R, et al: Continuous versus intermittent administration of ceftazidime in experimental klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agent Chemother 1986; 30: 403-408.
81. (81) Schentag JJ, Smith IL, Swanson DJ, et al: Role for dual individualization with cefmenoxime. Am J Med 1984; 77(Suppl 6A):43-50.
82. (82) Schito GC, Mannelli S, Pesce A, et al: Trends in the activity of macrolide and β-lactam antibiotics and resistance development. J Chemother 1997; 9(Suppl 3): 18-28.
83. (83) Sculier JP, Klastersky J: Gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984; 76: 429-435.
84. (84) Thornsberry C: Trends in antimicrobial resistance among to-day's bacterial pathogens. Pharmacotherapy 1995; 15:3S-8S.
85. (85) Vaudaux BP, Cherpillod J, Dayer P: Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother 1996; 37(Suppl C):45-51.
86. (86) Washington JA, Alexander Project Group: A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. Diagn Microbiol Infect Dis 1996; 25:183-190.
87. (87) Wise R: The pharmacokinetics of azithromycin. Rev Contemp Pharmacother 1994; 5:329-340.
88. (88) Woodford N, Adebiyi A-MA, Palepou M-FI, et al: Diversity of vana glycopeptide resistance elements in enterococci from humans and nonhuman sources. Antimicrob Agent Chemother 1998; 42: 502-508.
89. (89) Zinner SH, Dudley MN, Gilbert D, et al: Effect of dose and schedule on cefoperazone pharmacodynamics in an in vitro model of infection in a neutropenic host. Am J Med 1988; 85(Suppl 1A):56-58.